Poisoning of mitochondrial topoisomerase I by Lamellarin D

Molecular Pharmacology

Volumn 86, Issue 2, 2014, Pages 193-199

  Khiati, Salim ^a   Seol, Yeonee ^b   Agama, Keli ^a   Rosa, Ilaria Dalla ^a   Agrawal, Surbhi ^a   Fesen, Katherine ^a   Zhang, Hongliang ^a   Neuman, Keir C ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID DERIVATIVE; CAMPTOTHECIN; DNA TOPOISOMERASE; LAMELLARIN D; MITOCHONDRIAL DNA; UNCLASSIFIED DRUG;

ARTICLE; DNA CLEAVAGE; DNA DAMAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; PRIORITY JOURNAL;

CELL LINE, TUMOR; COUMARINS; DNA TOPOISOMERASES, TYPE I; DNA, MITOCHONDRIAL; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; ISOQUINOLINES; MITOCHONDRIA;

EID: 84903588697     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.092833     Document Type: Article

References (52)

1. Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, and Cushman M et al. (2007) Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res 67 :10397-10405. (Pubitemid 350070815)
2. Bailly C (2004) Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids. Curr Med Chem Anticancer Agents 4:363-378.
3. Ballot C, Kluza J, Martoriati A, Nyman U, Formstecher P, Joseph B, Bailly C, and Marchetti P (2009) Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D. Mol Cancer Ther 8:3307-3317.
4. Ballot C, Kluza J, Lancel S, Martoriati A, Hassoun SM, Mortier L, Vienne JC, Briand G, Formstecher P, and Bailly C et al. (2010) Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D. Apoptosis 15:769-781.
5. Burke TG and Mi Z (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37:40-46. (Pubitemid 24058811)
6. Canter JA, Kallianpur AR, Parl FF, and Millikan RC (2005) Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res 65:8028-8033. (Pubitemid 41297284)
7. Chamberlain GR, Tulumello DV, and Kelley SO (2013) Targeted delivery of doxorubicin to mitochondria. ACS Chem Biol 8:1389-1395.
8. Chinnery PF and Hudson G (2013) Mitochondrial genetics. Br Med Bull 106:135-159.
9. Clayton DA (1991) Replication and transcription of vertebrate mitochondrial DNA. Annu Rev Cell Biol 7:453-478.
10. Covey JM, Jaxel C, Kohn KW, and Pommier Y (1989) Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 49:5016-5022. (Pubitemid 19239335)
11. Das BB, Dexheimer TS, Maddali K, and Pommier Y (2010) Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. Proc Natl Acad Sci USA 107:19790-19795.
12. Dexheimer TS and Pommier Y (2008) DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat Protoc 3:1736-1750.
13. Douarre C, Sourbier C, Dalla Rosa I, Brata Das B, Redon CE, Zhang H, Neckers L, and Pommier Y (2012) Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism. PLoS ONE 7:e41094.
14. Facompré M, Tardy C, Bal-Mahieu C, Colson P, Perez C, Manzanares I, Cuevas C, and Bailly C (2003) Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res 63:7392-7399. (Pubitemid 37413481)
15. Gentry AC, Juul S, Veigaard C, Knudsen BR, and Osheroff N (2011) The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I. Nucleic Acids Res 39:1014-1022.
16. Greaves LC, Reeve AK, Taylor RW, and Turnbull DM (2012) Mitochondrial DNA and disease. J Pathol 226:274-286.
17. Heller A, Brockhoff G, and Goepferich A (2012) Targeting drugs to mitochondria. Eur J Pharm Biopharm 82:1-18.
18. Hsiang YH, Hertzberg R, Hecht S, and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878. (Pubitemid 16211028)
19. Hsu CW, Yin PH, Lee HC, Chi CW, and Tseng LM (2010) Mitochondrial DNA content as a potential marker to predict response to anthracycline in breast cancer patients. Breast J 16:264-270.
20. Hunter SE, Jung D, Di Giulio RT, and Meyer JN (2010) The QPCR assay for analysis of mitochondrial DNA damage, repair, and relative copy number. Methods 51:444-451.
21. Ioanoviciu A, Antony S, Pommier Y, Staker BL, Stewart L, and Cushman M (2005) Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem 48 :4803-4814. (Pubitemid 41033123)
22. Kluza J, Gallego MA, Loyens A, Beauvillain JC, Sousa-Faro JM, Cuevas C, Marchetti P, and Bailly C (2006) Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. Cancer Res 66:3177-3187.
23. Koster DA, Palle K, Bot ESM, Bjornsti M-A, and Dekker NH (2007) Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 448:213-217. (Pubitemid 47067371)
24. Li Q, Jiang J, Fan A, Cui Y, and Jia Y (2011) Total synthesis of lamellarins D, H, and R and ningalin B. Org Lett 13:312-315.
25. Low RL, Orton S, and Friedman DB (2003) A truncated form of DNA topoisomerase IIbeta associates with the mtDNA genome in mammalian mitochondria. Eur J Biochem 270:4173-4186. (Pubitemid 37281636)
26. Lu J, Sharma LK, and Bai Y (2009) Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res 19:802-815.
27. Marrache S and Dhar S (2012) Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci USA 109:16288-16293.
28. Medikayala S, Piteo B, Zhao X, and Edwards JG (2011) Chronically elevated glucose compromises myocardial mitochondrial DNA integrity by alteration of mitochondrial topoisomerase function. Am J Physiol Cell Physiol 300:C338-C348.
29. Naito A, Carcel-Trullols J, Xie CH, Evans TT, Mizumachi T, and Higuchi M (2008) Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line. Int J Cancer 122:1506-1511. (Pubitemid 351294958)
30. Neuzil J, Dong LF, Rohlena J, Truksa J, and Ralph SJ (2013) Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion 13:199-208.
31. Nitiss J and Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85:7501-7505.
32. Olszewska A and Szewczyk A (2013) Mitochondria as a pharmacological target: magnum overview. IUBMB Life 65:273-281.
33. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, and Hosseini SH et al. (2005) mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 102:719-724. (Pubitemid 40282732)
34. Pla D, Albericio F, and Alvarez M (2008) Recent advances in lamellarin alkaloids: isolation, synthesis and activity. Anticancer Agents Med Chem 8:746-760.
35. Pommier Y (2013) Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8:82-95.
36. Pommier Y, Leo E, Zhang H, and Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17:421-433.
37. Pommier Y and Marchand C (2012) Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 11:25-36.
38. Pourquier P, Ueng LM, Fertala J, Wang D, Park HJ, Essigmann JM, Bjornsti MA, and Pommier Y (1999) Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8- oxoguanine and 5-hydroxycytosine. J Biol Chem 274:8516-8523. (Pubitemid 29164641)
39. Ray Chaudhuri A, Hashimoto Y, Herrador R, Neelsen KJ, Fachinetti D, Bermejo R, Cocito A, Costanzo V, and Lopes M (2012) Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat Struct Mol Biol 19 :417-423.
40. Rowe TC, Weissig V, and Lawrence JW (2001) Mitochondrial DNA metabolism targeting drugs. Adv Drug Deliv Rev 49:175-187. (Pubitemid 32493807)
41. Seol Y, Zhang H, Pommier Y, and Neuman KC (2012) A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity. Proc Natl Acad Sci USA 109:16125-16130.
42. Singh KK, Russell J, Sigala B, Zhang Y, Williams J, and Keshav KF (1999) Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 18:6641-6646.
43. Sobek S, Dalla Rosa I, Pommier Y, Bornholz B, Kalfalah F, Zhang H, Wiesner RJ, von Kleist-Retzow JC, Hillebrand F, Schaal H, Mielke C, Christensen MO and Boege F (2013) Negative regulation of mitochondrial transcription by mitochondrial topoisomerase I. Nucleic Acids Res 41:9848-9457.
44. Stewart L, Redinbo MR, Qiu X, Hol WG, and Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534-1541. (Pubitemid 28217077)
45. Subramanian D, Kraut E, Staubus A, Young DC, and Muller MT (1995) Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 55:2097-2103.
46. Takebayashi Y, Pourquier P, Yoshida A, Kohlhagen G, and Pommier Y (1999) Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci USA 96:7196-7201. (Pubitemid 29299638)
47. Tanizawa A, Fujimori A, Fujimori Y, and Pommier Y (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842. (Pubitemid 24164661)
48. Wang Y, Lyu YL, and Wang JC (2002) Dual localization of human DNA topoisomerase IIIalpha to mitochondria and nucleus. Proc Natl Acad Sci USA 99:12114-12119.
49. Wisnovsky SP, Wilson JJ, Radford RJ, Pereira MP, Chan MR, Laposa RR, Lippard SJ, and Kelley SO (2013) Targeting mitochondrial DNA with a platinum-based anticancer agent. Chem Biol 20:1323-1328.
50. Yousif LF, Stewart KM, and Kelley SO (2009) Targeting mitochondria with organelle-specific compounds: strategies and applications. ChemBioChem 10:1939-1950.
51. Zhang H, Barceló JM, Lee B, Kohlhagen G, Zimonjic DB, Popescu NC, and Pommier Y (2001) Human mitochondrial topoisomerase I. Proc Natl Acad Sci USA 98:10608-10613. (Pubitemid 32878668)
52. Zhang H and Pommier Y (2008) Mitochondrial topoisomerase I sites in the regulatory D-loop region of mitochondrial DNA. Biochemistry 47:11196-11203.